Figures
Abstract
Objectives
The aim of this study was to evaluate the frequency of transaminase elevations (TE) and total bilirubin elevations (TBE) during the first year of therapy with a single tablet regimen including RPV/FTC/TDF (EPA) in HIV/hepatitis C virus (HCV)-coinfected subjects in clinical practice.
Methods
In a retrospective analysis, HIV/HCV-coinfected subjects who started EPA at 17 centres throughout Spain were included as cases. Subjects who started an antiretroviral therapy (ART) other than EPA during the study period at the same hospitals were randomly selected as controls in a 1:2 ratio. Primary outcome variables were grade (G) 3–4 TE and G4 TBE.
Results
Of the 519 subjects included, 173 individuals started EPA. Nine (5.2%) subjects of the EPA group and 49 (14.2%) controls were naïve to ART. The median (Q1–Q3) follow-up was 11.2 (9.7–13.9) months. TE was observed in 2 [1.2%; 95% confidence interval (CI): 0.14%–4.1%] subjects receiving EPA and 11 (3.2%; 95%CI: 1.6%–5.6%) controls (p = 0.136), all events were G3. No patient discontinued ART due to TE. One (0.6%; 95%CI: 0.01%–3.1%) subject on EPA and 8 (2.3%; 95%CI: 1%–4.5%) subjects in the control group developed TBE (p = 0.141), without developing any other hepatic event during follow-up. Three (2.3%) subjects with cirrhosis versus 10 (3.1%) without cirrhosis showed G3-4 TE (p = 0.451).
Citation: Neukam K, Espinosa N, Collado A, Delgado-Fernández M, Jiménez-Aguilar P, Rivero-Juárez A, et al. (2016) Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study. PLoS ONE 11(5): e0155842. https://doi.org/10.1371/journal.pone.0155842
Editor: Wenyu Lin, Harvard Medical School, UNITED STATES
Received: January 7, 2016; Accepted: May 5, 2016; Published: May 19, 2016
Copyright: © 2016 Neukam et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: KN is the recipient of a Miguel Servet research grant from the Instituto de Salud Carlos III (grant number CP13/00187). AR-J is the recipient of a post-doctoral extension grant of the Fundación Progreso y Salud of the Junta de Andalucía (grant number RH-0024-2013). JM is the recipient of a grant from the Servicio Andaluz de Salud de la Junta de Andalucía (B-0037). JAP is the recipient of an intensification grant from the Instituto de Salud Carlos III (grant number Programa-I3SNS). This work was partially funded by Gilead Sciences SL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: KN has received lecture fees from Janssen-Cilag, Roche, Bristol-Meyers Squibb and Merck Sharp & Dohme and has received research support from Janssen-Cilag, Bristol-Meyers Squibb, Merck Sharp & Dohme, Gilead Sciences and Abbott Pharmaceuticals. AC reports having received consultancy fees from Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead Sciences, Pfizer and AbbVie. ARJ has received lecture fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, ViiV Healthcare and Roche. DM reports having received consultancy fees from Janssen Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead Sciences, AbbVie and ViiH Healthcare. JM has received lectures fees from Roche, Gilead Sciences, Merck Sharp & Dome, Boehringer Ingelheim, Janssen-Cilag and Bristol-Myers Squibb and consulting fees from Roche, Gilead Sciences, Boehringer Ingelheim, Bristol Myers-Squibb and Merck Sharp & Dome. JAP reports having received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott Pharmaceuticals, Gilead Sciences, Merck Sharp & Dohme, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees from GlaxoSmithKline, Roche, Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, Boehringer Ingelheim and Schering-Plough. All other authors: none to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Introduction
Antiretroviral therapy (ART) may lead to hepatotoxic events, such as liver enzyme elevations, acute liver failure and death [1]. These events occur more frequently in HIV/HCV-coinfected subjects as compared to HIV monoinfected patients [2–6]. Liver toxicity at the beginning of the ART era was relatively common in HIV/HVC-coinfected subjects, with high risk of severe and eventually fatal hepatic events. Among non-nucleoside reverse transcriptase inhibitors (NNRTI), nevirapine demonstrated a higher risk of hepatotoxicity as compared to efavirenz (EFV) [7] and among protease inhibitors (PIs), tipranavir and higher doses of ritonavir were more toxic than other members of this drug family [8]. However, most of these drugs are not used nowadays. Conversely, newer antiretroviral drugs, such as boosted atazanavir (ATV) or darunavir (DRV), as well as integrase inhibitors, have been associated to a lower rate of toxic liver events in the clinical practice [2,6,9].
Rilpivirine is a newer NNRTI that is given coformulated with tenofovir and emtricitabine as a single tablet regimen (EPA) or as single drug along with other antiretroviral drugs. In a pooled analysis of the two pivotal phase III clinical trials on RPV, the hepatic safety profile in subjects with chronic viral hepatitis appeared somewhat poorer as compared to HIV-monoinfected subjects [10]. However, due to the relatively low frequency of HIV/HCV-coinfected patients in these studies, these figures need confirmation and additionally, these studies did not evaluate a single tablet regimen (STR). The STaR and SPIRIT clinical trials did evaluate these drugs in a STR, however, likely due to the low number of patients with HCV and/or HBV coinfection, no data on hepatic safety in this subpopulation is available [11,12]. Finally, no data on this topic based on routine clinical data are available. Consequently, studies on the hepatic safety of EPA, particularly those based on real-life experience, are warranted.
The aim of the present study was to evaluate the frequency of severe hepatic toxicity, defined as grade 3 or 4 transaminase elevations (TE) or grade 4 total bilirubin elevations (TBE), during the first 48 weeks of EPA in HIV-infected subject with chronic HCV infection.
Patients and Methods
Study design and study population
In a retrospective case-control study, all patients consecutively seen at the Infectious Diseases Units of 17 Spanish hospitals between November 2012 and February 2014, were selected disregarding the presence or severity of hepatic toxicities if they fulfilled the following criteria: i) Older than 18 years; ii) HIV-1 infection, as diagnosed on the basis of the presence of serum HIV antibodies detected by EIA and western-blot; iii) Chronic HCV infection as confirmed by detectable plasma HCV-RNA; iv) Starting a new antiretroviral drug regimen; v) Exposure to study drugs for at least one week; vi) Clinical visits and blood tests available at baseline and, at least, after 12, 24 and 48 weeks thereafter, unless treatment was discontinued for any reason. In those patients who received therapy against HCV-infection, follow-up was stopped at the moment of anti-HCV treatment initiation. Likewise, treatment interruption due to any reason required immediate stop of follow-up resulting to drug exposure being reflected by the time of follow-up.
ART Regimens
Out of the overall population included in the database, patients naïve for RPV were selected in a 1:2 (case/control) ratio according to the following regimens: i) Cases (EPA group): All patients who had started EPA during the study period and ii) Controls: Subjects who initiated any ART that did not include RPV during the study period. The control group was randomly selected out of all the patients with ART changes or initiation of one or more new antiretroviral drugs in the participant hospitals.
Definition of liver enzyme and bilirubin elevations
Grade 3 TE were defined as elevations of alanine-aminotransferase (ALT) or aspartate-aminotransferase (AST) between 5 and 10 times above the upper level of normality (ULN) among patients who had normal baseline levels. Grade 4 TE were defined as ALT or AST increases greater than 10 times the ULN. In patients with elevated baseline ALT or AST levels, 3.5- to 5-fold increase from baseline levels were considered grade 3 TE and greater than 5-fold elevations were defined as grade 4 TE. Grade 1 and grade 2 TE was analysed in those patients with baseline ALT and AST values below the ULN and were defined as ALT or AST levels 1.25 to 2.5-fold and 2.5 to 5-fold above the ULN, respectively. Grade 4 TBE were defined as increases of total bilirubin equal or greater than 5 mg/dL. Likewise, grade 1, grade 2 and grade 3 TBE were considered when total bilirubin levels were ≥1.1 mg/dL to <1.6 mg/dL, ≥1.6 mg/dL to <2.6 mg/dL and ≥2.6 mg/dL to <5 mg/dL, respectively [13].
Liver fibrosis assessment
Baseline advanced fibrosis and cirrhosis was diagnosed when stage 3 (F3) or stage 4 (F4) according to the Scheuer index was detected in a liver biopsy [14]. If biopsy was not available, transient elastography cut-off values of ≥9.5 kPa for advanced fibrosis and ≥14.6 kPa for cirrhosis were applied [15,16]. In patients without liver biopsy or liver stiffness measurement, advanced fibrosis was excluded when baseline FIB-4 index was ≤1.45 and diagnosed when baseline FIB-4 values were ≥3.25 [17]. Both liver biopsy and transient elastography were considered valid if obtained within six months before or after ART initiation. In the case of F4, a 12 month-period before ART initiation was allowed.
Statistical analysis
The frequency of subjects who present grade 3 or 4 TE and/or grade 4 TBE, as well as of those who discontinue ART due to adverse events, were assessed and the 95% confidence interval (CI) was calculated. Comparisons of continuous variables were carried out by means of the Student’s t-test or the Mann-Whitney U-test, when applicable. To compare categorical variables, the χ2 test or the Fisher’s exact test were used. In order to compare the CD4 cell counts and the HIV viral loads at baseline and the end of follow-up, the Wilcoxon Signed Rank test and the McNemar test were applied, respectively. A univariate analysis was carried out to identify baseline factors associated with hepatic toxicity. Subsequently, a multivariate logistic regression analysis was applied, adjusting for age, sex, as well as those factors that were associated with a p<0.2 in the univariate analysis. Statistical analysis and control randomization was performed using the SPSS statistical software package release 22.0 (IBM, Chicago, IL, USA) and R i386 3.0.1 (The R Foundation for Statistical Computing, Boston, USA).
Results
Characteristics of the patients
One hundred and seventy-three patients who initiated EPA were included in this study. Accordingly, 346 controls were randomly selected. Median (IQR) age was 47.6 (43.7–50.8) years and 427 (82.3%) were male. The demographic and baseline characteristics of the study population are listed in Table 1. Table 2 lists the reasons for ART initiations by treatment group.
EPA: RPV/TDF/FTC group.
ART regimens in the control group
Triple therapy with a NRTI backbone among the controls was mainly based on TDF/FTC, which was administered to 165 (47.7%) patients. NRTI-sparing regimens were administered to 92 (26.6%) individuals and abacavir (ABC)/ lamivudine (3TC) were provided to 59 (17.1%) subjects. A total of 475 drug initiations were registered in the control group. The newly introduced drugs are summarized in Table 3.
Follow-up
The median (IQR) follow-up of the study patients was 11.2 (6.2–12.4) months for the EPA group and 11.2 (7.8–12.5) months for the control group (p = 0.856), 362 (70%) subjects reached the scheduled end of follow-up. The numbers of patients who did not reach week 12 of therapy were 8 (4.6%) for the EPA group and 27 (7.8%) for the control group (p = 0.173). Therapy against HCV infection was initiated after 4.9 (3–9.7) months in the EPA group and 3.8 (2.5–6.8) months (p = 0.269). The detailed outcome for the two study populations is shown in Fig 1. The number of patients with plasma HIV RNA below 50 copies/mL at baseline versus after 12 months of follow-up was 133 (76.9%) versus 91 (89.2%; p = 0.263) among the patients who received EPA and 170 (49.1%) versus 169 (84.5%; p<0.001) in the control group (p = 0.173), respectively. Median (IQR) CD4 cell counts at baseline versus the end of follow-up were 515 (332–764) cells/mL versus 606 (362–819) cells/mL (p = 0.092) in the EPA group and 398 (240–589) cells/mL versus 465 (295–696) cells/mL (p<0001) among the controls.
EPA: RPV/TDF/FTC group. None of the outcomes showed statistically significant differences between the two groups.
Liver safety
Grade 3 TE was observed in 2 (1.2%; 95%CI: 0.14%-4.1%) individuals receiving EPA and in 11 (3.2%; 95%CI: 1.6%-5.6%) patients of the control group (p = 0.136). All grades of TE according to the study group are summed up in Table 4. No episode of grade 4 TE during the study period was detected. In the EPA group, grade 3 TE episodes were observed after 24.4 and 25.6 weeks of therapy, respectively. In the control group, the time (IQR) to grade 3 TE was 16.4 (13–37.8) weeks. Among the subgroup of patients who initiated the new ART due to simplification, adverse events to prior ART or due to interactions, 2 (1.7%) patients who received EPA and 6 (3.8%) subjects of the control group showed grade 3 TE (p = 0.251).
Grade 4 TBE were identified in 1 (0.6%; 95%CI: 0.01%-3.1%) patients on EPA and in 8 (2.3%; 95%CI: 1%-4.5%; p = 0.141) subjects of the control group. Of the latter, 7 patients received ritonavir-boosted atazanavir as part of their ART regimen. Other TBE grades according to study group are shown in Table 4. No patient discontinued ART due to liver toxicity and none of those individuals who developed grade 3 or 4 TE or grade 4 TBE developed other hepatic events during the follow-up.
Fourteen (8%; 95%CI: 4.4%-13%) of the EPA group and 18 (5.2%; 95%CI: 3.1%-8.1%) of the control group discontinued therapy due to any adverse event. Hepatic decompensations during the study period were observed in one (0.6%; 95%CI: 0.001%-3.2%) patient who received EPA and in 6 (1.7%; 95%CI: 0.6%-3.7%) subjects from the control group. The patient receiving EPA presented hepatic encephalopathy and portal hypertensive gastrointestinal bleeding. The episodes observed within the control group were: hepatic encephalopathy (5 patients), ascites (two patients) and portal hypertensive gastrointestinal bleeding (one patient). One (0.6%) patient of the EPA group and 8 (2.3%) patients of the control group died during the period of follow-up. Death due to hepatic events was observed in 1 (0.6%) patient of the EPA group and 2 (0.2%) patients of the control group (p = 0.741).
A total of 3 (1.5%) subjects with advanced fibrosis (F≥3) versus 10 (3.8%) without advanced fibrosis (F<3) showed grade 3 or 4 TE (p = 0.129). The corresponding figures for subjects with and without cirrhosis were 3 (2.3%) subjects and 10 (3.1%) patients, respectively (p = 0.451). The proportions of severe TE according to liver damage and within the study groups are shown in Fig 2.
Grade 3 transaminase elevations (TE) according to the presence of advanced fibrosis (2A) or cirrhosis (2B) at baseline by treatment group. EPA: RPV/TDF/FTC group.
Predictors of grade 3 or 4 TE and grade 4 TBE
In the multivariate analysis, no predictors of grade 3 or 4 TE could be identified (Table 5). The initiation of ritonavir-boosted atazanavir was the only factor independently associated with grade 4 TBE (Table 6).
Discussion
The present study shows that the frequency of grade 3 or 4 TE or grade 4 TBE is very low in HIV/HCV-coinfected patients who receive EPA in the clinical practice. Furthermore, all TE were grade 3 and these hepatotoxic events did not lead to treatment discontinuation.
To date, the little data available on hepatotoxic events in HIV/HCV-coinfected patients who receive RPV is derived from clinical trials. On the one hand, the rates of grade 3 or 4 ALT elevations reported herein are somewhat lower than what was reported in the TMC278-C204 phase II clinical trial, where a frequency of 6% was observed in a population that consisted mainly of patients without HCV coinfection [18]. However, the presence of elevated baseline ALT or AST levels was not taken into account for the definition of TE and therefore, comparisons of these results with those from the present study are difficult to interpret. On the other hand, in a pooled analysis of data derived from the ECHO and the THRIVE clinical trials conducted by Nelson et al [10], TE were among the most frequent adverse events in HCV or hepatitis B virus (HBV)-coinfected subjects receiving RPV in combination with TDF/FTC. In this context, 20.4% of the patients showed grade 2–4 AST elevations and 33.3% of the subjects presented grade 2–3 ALT elevations. However, as it was also the case for TMC278-C204, the number of patients with viral hepatitis was very low in these trials, with only 49 HCV and/or HBV-coinfected patients at baseline and consequently, inferential statistics comparing grade 2–4 TE between patients with and without viral hepatitis were not possible. Furthermore, ART was not applied as a single tablet regimen in these trials and no analysis to distinguish between grade 2 and 3–4 TE was conducted, therefore, the results cannot be compared with the present work. Although results of the STaR and the SPIRIT trials are available, in which EPA was given in a single-tablet regimen in combination with food, unfortunately no specific data on TE or TBE have been published for the coinfected subpopulation [11,12]. Also, over 96% of the participants in these trials did not show HCV coinfection. In contrast, the study described herein includes a high number of HIV-infected subjects with active HCV infection at baseline. Importantly, the frequencies of grade 3 or 4 TE and grade 4 TBE in patients receiving EPA were not only low, they also tended to be under to what is observed for commonly administered ART, as represented by the control group.
Apart from the low frequency of hepatotoxic events, it is important to underline that TE episodes in patients who were given EPA were mild. In this context, no grade 4 TE were observed. Additionally, none of the TE resulted in drug discontinuation. This is an important finding, since patients in a real-life setting may be less motivated to tolerate adverse events and regimens may be switched earlier. Of note, the rate of discontinuations due to liver adverse events or liver-related death was generally low in the EPA group. Finally, the presence of advanced fibrosis or cirrhosis was not associated with an increased risk of grade 3 or 4 TE or grade 4 TBE in patients receiving EPA, which stands in accordance with earlier findings [7,9,19,20]. All this adds up to the safety of EPA in patients with HCV coinfection and is especially important since hepatic safety in cirrhotic patients is crucial for drug selection in this population.
Several studies [7,9,21–24] have assessed the impact of different third agents used in combination with a backbone of two NRTI in subjects with chronic viral hepatitis. These studies found that EFV [7,9] and nevirapine [7] are associated with 5.9–6.6% and 11% of grade 3–4 TE and 2.2–2.6% and 0.8% of grade 4 TBE, PI/r [7,9,21–24] with 8.1–10.5% of grade 3–4 TE and 3.7–15% of grade 4 TBE and raltegravir (RAL) [19] with 9.3% of grade 3–4 TE and 1.9% of grade 4 TBE. Although it is not possible to draw definite conclusions from comparing different studies, given that the cited studies were designed and conducted similar to the present work, EPA appears to be less hepatotoxic than the drugs examined in the other studies.
This study has limitations. First, due to the retrospective character of the study, self-limited hypertransaminasemia may have passed undetected. However, a adequate follow-up was inclusion criteria for this study and it can therefore be ruled out that an episode of severe liver toxicity has gone unnoticed. Second, drugs that were approved after the end of the inclusion period, as dolutegravir and elvitegravir/cobicistat, were not administered to the control group. Still, this study was not aimed to compare specific regimens of the control group and further studies are warranted to clarify this issue.
In conclusion, the frequency of severe liver toxicity in HIV-infected subjects with chronic hepatitis C receiving EPA is very low in the clinical practice. Taken together with the findings that TE episodes in the EPA group were generally mild and did not lead to drug discontinuation, all these data suggest that EPA can be safely used in this particular subpopulation.
Acknowledgments
Other members of the hEPAtic study group were: Teresa Aldámiz-Echevarría, José Ramón Arribas López, Otilia Bisbal, Javier Borrallo Torrejón, Ignacio de los Santos-Gil, Marta Díaz Menéndez, Cristina Díez, Lourdes Domínguez, Elisa Fernández-Fuertes, Juan González-García, Juan Carlos López, Juan Macías Sánchez, María Mancebo Hernández, Onofre Martínez, Lorena Martínez Fernández, Mariano Matarranz, Pilar Miralles, María Luisa Montes Ramírez, Patricia Monje Agudo, Alberto Romero Palacios, Francisco Parras, Federico Pulido, Francisco Tejerina, Antonio Vergara de Campos.
Author Contributions
Conceived and designed the experiments: KN JAP. Performed the experiments: KN NE A. Collado MD-F PJ-A AR-J VH-A AG-B JR-M DM A. Carrero FT MJR JH-Q ML-S IP-C FV-M JM JAP. Analyzed the data: KN JAP. Wrote the paper: KN JAP.
References
- 1. Pineda JA, Macias J, Mira JA, Merchante N, del Valle J, Neukam KI. (2010) HAART and the liver: friend or foe? Eur J Med Res; 15: 93–96. pmid:20452892
- 2. Di Biagio A, Nicolini LA, Lorenzini P, Puoti M, Antinori A, Cozzi-Lepri A, et al. (2014) Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort. HIV Clin Trials; 15: 151–160 pmid:25143024
- 3. Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M. (2012) Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection. HIV Clin Trials; 13: 171–177. pmid:22592097
- 4. Van Welzen B, Mudrikova T, Arends J, Hoepelman A. (2012) No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients. HIV Med; 13: 448–452. pmid:22413955
- 5. Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, et al. (2015) Risk of Liver Enzyme Elevation during Treatment with Ritonavir-boosted Protease Inhibitors among HIV-monoinfected and HIV/HCV Coinfected Patients. J Acquir Immune Defic Syndr 69: 312–318. pmid:25723139
- 6. Vispo E, Fernández-Montero JV, Labarga P, Barreiro P, Soriano V. (2013) Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS; 27: 1187–11888. pmid:23739226
- 7. Macias J, Neukam K, Mallolas J, Lopez-Cortes LF, Carton JA, Domingo P, et al. (2012) Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin Trials; 13: 61–69. pmid:22510353
- 8. Jones M, Nunez M. (2011) HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS; 6: 546–552. pmid:22001896
- 9. Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A et al. (2011) Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother; 66: 2605–2614. pmid:21903660
- 10. Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, et al. (2012) Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother; 67: 2020–2028. pmid:22532465
- 11. Cohen C, Wohl D, Arribas JR, Henry K, Van Lunzen J, Bloch M, et al. (2014) Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS; 28: 989–997. pmid:24508782
- 12. Palella FJ Jr, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, et al. (2014) Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS; 28: 335–344. pmid:24670520
- 13.
World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2010). Available at http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Last date accessed: 20th of December 2015.
- 14. Scheuer PJ. (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol; 13: 372–374. pmid:1808228
- 15. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology; 128: 343–350. pmid:15685546
- 16. Vergara S, Macias J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, et al. (2007) The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis; 45: 969–974. pmid:17879910
- 17. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology; 43: 1317–1325. pmid:16729309
- 18. Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, et al. (2012) Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses; 28: 437–446. AIDS 2014; 28: 335–344. pmid:21902621
- 19. Macias J, Neukam K, Portilla J, Iribarren JA, de LS I, Rivero A, et al. (2011) Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother; 66: 1346–1350. pmid:21398295
- 20. Casado JL, Mena A, Bañón S, Moreno A, Castro A, Perez-Elías MJ, et al. (2014) Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis. J Int AIDS Soc; 17 (4 Suppl 3): 19574. pmid:25394081
- 21. Macias J, Orihuela F, Rivero A, Viciana P, Marquez M, Portilla J, et al. (2009) Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. J Antimicrob Chemother; 63: 178–183. pmid:18952618
- 22. Merchante N, Lopez-Cortes LF, Delgado-Fernandez M, Rios-Villegas MJ, Marquez-Solero M, Merino D, et al. (2011) Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. AIDS Patient Care STDS; 25: 395–402. pmid:21688986
- 23. Mira JA, Macias J, Giron-Gonzalez JA, Merino D, Gonzalez-Serrano M, Jimenez-Mejias ME, et al. (2006) Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother; 58: 140–146. pmid:16720565
- 24. Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, et al. (2008) Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother; 61: 925–932. pmid:18276600